Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma
Autore:
Davis, TA; Hsu, FJ; Caspar, CB; van Beckhoven, A; Czerwinski, DK; Liles, TM; Taidi, B; Benike, CJ; Engleman, EG; Levy, R;
Indirizzi:
Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA Stanford UnivStanford CA USA 94305 , Dept Pathol, Stanford, CA 94305 USA Stanford Univ, Sch Med, Div Med Oncol, Stanford, CA 94305 USA Stanford Univ Stanford CA USA 94305 Div Med Oncol, Stanford, CA 94305 USA
Titolo Testata:
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
fascicolo: 9, volume: 7, anno: 2001,
pagine: 517 - 522
SICI:
1083-8791(2001)7:9<517:IVFACS>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; DENDRITIC CELLS; SURFACE-IMMUNOGLOBULIN; RECONSTITUTION; IMMUNIZATION; BLOOD; IMMUNOTHERAPY; THERAPY; TUMORS;
Keywords:
KLH; idiotype vaccination; anti-Id response; non-Hodgkin's lymphoma;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Levy, R Stanford Univ, Div Oncol, Sch Med, Dept Med, CCSR 1126,296 Campus Dr, Stanford, CA 94305 USA Stanford Univ CCSR 1126,296 Campus Dr Stanford CA USA 94305 05 USA
Citazione:
T.A. Davis et al., "Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma", BIOL BLOOD, 7(9), 2001, pp. 517-522

Abstract

Vaccination with the idiotype (Id) protein derived from B-cell malignancies can produce Id-specific immune responses that correlate with improved remission duration and survival rates in patients with follicular non-Hodgkin's lymphoma (NHL). A state of minimal or no residual disease correlates strongly with the laboratory detection of a cellular or humoral immune response. High-dose cytotoxic therapy (HDCT) with autologous stem cell support (autologous bone marrow transplantation [ABMT]) can provide profound cytoreduction of B-cell NHL, but the potential immune suppression associated with myeloablative therapy may compromise a patient's ability to mount a specific immune response. To determine whether patients with NHL could mount detectable immune responses following ABMT, Id vaccines were administered at 2 to 12 months following myeloablative therapy to a series of patients with relapsed or resistant B-cell NHL. Two different vaccination strategies produced robust immune responses against KLH in all patients, supporting the capacity of the reconstituted immune system following HDCT to react against a strong antigen. Combining the results from both vaccination strategies, 10 of 12 patients mounted Id-specific humoral or cellular responses. Vaccinations were consistently well tolerated. Of the 12 patients, 7 have experienced prolonged remissions with a follow-up from HDCT ranging from 3 to more than 11 years. Our experience serves to document the ability of the recovering immune system to react against both self and xenotypic antigens and supports the feasibility and safety of antigen-specific vaccination following myeloablative therapy in patients with B-cell NHL.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 10:19:25